An interventional study of Cala Device in Parkinson Disease, sponsored by Cala Health, Inc.. Completed at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Cala Health, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 554th largest by enrollment of the 1,257 interventional ones that give a count, is one of 90 that started in 2020, is one of 586 with no phase, and was the 1,192nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,650 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 90 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,257 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,650 have an industry lead sponsor. The 10 most frequent:
Cala Health, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Cala Health, Inc. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
| NCT06447207Colorado State UniversityOccupational Therapy Led Social Prescription for People With Parkinson Disease | 2026-11-30 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,650 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor
40 patients with PD with at least mild postural tremor were enrolled in a four-week, prospective, single-arm, open-label study of twice daily TAPS therapy. Due to the COVID-19 pandemic, TAPS devices were shipped to patients to run the study remotely. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
postural tremor as defined by:
Willing to comply with study protocol requirements including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two 40-minute TAPS sessions daily for 28 days, recommended as once in the morning and once in the evening.
Device: Cala Device
transcutaneous afferent patterned stimulation (TAPS)
Tremor Power
Pre-specified effectiveness endpoints included improvements in (1) objective postural tremor power (primary outcome; assessed using an accelerometer on the device under standard of care medication state at home).
Time frame: 4 weeks
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Improvement of clinician-ratings of Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part III \[Goetz, C.G. et al. Wiley Intersci. 2008\] (co-secondary; in medication-off state). Clinician rated patients' tremor pre and post therapy on a scale of 0-4. 0=Normal (no tremor), 4=Severe.
Time frame: 4 weeks
Bain and Findley Activities of Daily Living (BF-ADL)
Improvement of patient-ratings of the Bain and Findley Activities of Daily Living (BF-ADL) \[Bain PG, et al. Journal of Neurol, Neuros \& Psych 1993\] (co-secondary; in medication-off state). Patients' rated ability to perform specific activities pre and post therapy on a scale from 1-4. 1=Able to do the activity without difficulty, 4=Cannot do the activity by yourself.
Time frame: 4 weeks
Percentage of Patients With Clinician and Patient Global Impressions of Improvement Rated < 4 (CGI-I, PGI-I)
Clinician and Patient global impressions of improvement (CGI-I, PGI-I; exploratory) post therapy. This is a rated scale from 1-7, with 1=Very Much Improved to 7=Very Much Worse. Percentage of patients with ratings \< 4 (including very much improved, much improved and improved) were computed respectively for CGI-I and PGI-I.
Time frame: 4 weeks
| Milestone | TAPS Delivered by Cala Device |
|---|---|
| Started | 40 |
| Completed | 37 |
| Not completed | 3 |
Pre-specified effectiveness endpoints included improvements in (1) objective postural tremor power (primary outcome; assessed using an accelerometer on the device under standard of care medication state at home).
| Percentage of tremor power reduction | Single Arm - TAPS Delivered by Cala Device |
|---|---|
| Tremor Power | 64 (54 to 79) |
Improvement of clinician-ratings of Movement Disorder Society Unified PD Rating Scale (MDS-UPDRS) Part III \[Goetz, C.G. et al. Wiley Intersci. 2008\] (co-secondary; in medication-off state). Clinician rated patients' tremor pre and post therapy on a scale of 0-4. 0=Normal (no tremor), 4=Severe.
| units on a scale | Single Arm - TAPS Delivered by Cala Device |
|---|---|
| Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | 0.6 ± 0.5 |
Improvement of patient-ratings of the Bain and Findley Activities of Daily Living (BF-ADL) \[Bain PG, et al. Journal of Neurol, Neuros \& Psych 1993\] (co-secondary; in medication-off state). Patients' rated ability to perform specific activities pre and post therapy on a scale from 1-4. 1=Able to do the activity without difficulty, 4=Cannot do the activity by yourself.
| units on a scale | Single Arm - TAPS Delivered by Cala Device |
|---|---|
| Bain and Findley Activities of Daily Living (BF-ADL) | 0.5 ± 0.5 |
Clinician and Patient global impressions of improvement (CGI-I, PGI-I; exploratory) post therapy. This is a rated scale from 1-7, with 1=Very Much Improved to 7=Very Much Worse. Percentage of patients with ratings \< 4 (including very much improved, much improved and improved) were computed respectively for CGI-I and PGI-I.
| percentage of patients with improvement | Single Arm - TAPS Delivered by Cala Device |
|---|---|
| PGI-I | 80 |
| CGI-I | 77 |
Collected over 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAPS Delivered by Cala Device | 0/40 (0%) | 0/40 (0%) | 8/40 (20%) |
| Event | TAPS Delivered by Cala Device |
|---|---|
| sore/lesionSkin and subcutaneous tissue disorders | 2/40 |
| Unsteady gaitGeneral disorders | 1/40 |
| significant and persistent skin irritationSkin and subcutaneous tissue disorders | 1/40 |
| persistent pain from stimulationMusculoskeletal and connective tissue disorders | 1/40 |
| significant discomfort with stimulationGeneral disorders | 1/40 |
| twitching of ring fingerMusculoskeletal and connective tissue disorders | 1/40 |
| anxiety/insomnia/worsening of tremor at nightGeneral disorders | 1/40 |
40 enrolled subjects with PD
| Age, Continuous(years) | TAPS Delivered by Cala Device |
|---|---|
| Mean | 67.1 ± 9.9 |
| Sex: Female, Male(Participants) | TAPS Delivered by Cala Device |
|---|---|
| Female | 10 |
| Male | 30 |
| Race/Ethnicity, Customized(Participants) | TAPS Delivered by Cala Device |
|---|---|
| Race — Asian | 6 |
| Race — African American | 1 |
| Race — Caucasian | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2020 to primary completion in Mar 2021, 4 months.
Results were first posted in Feb 2024, 2 years 11 months after primary completion.
Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 4 months is below that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cala Health, Inc.